Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

>2 years6-10 visitsEfficacy phase (II)No PlaceboStandard MedicinesOralDiabetologyEndocrinologyHepatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nicotinamide
Nicotinamide is a form of vitamin B3 that supports body energy processes and helps maintain healthy skin.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Universitari Germans Trias I Pujol
Endocrinología y Nutrición
Badalona, Spain
Hospital De La Santa Creu I Sant Pau
Endocrinología y Nutrición
Barbastro, Spain
Sponsor: Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.